

RESOLUTIONS PASSED AT THE ANNUAL GENERAL MEETING HELD ON 26 SEPTEMBER 2024

Capitalised terms used herein, unless otherwise defined, shall have the definitions ascribed to them in the annual report of the Company for the financial year ended 31 May 2024 (“**AR2024**”) which was despatched to shareholders of HC Surgical Specialists Limited (the “**Company**”) on 4 September 2024.

The Board of Directors of the Company is pleased to announce that, pursuant to Rule 704(15) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist (the “**Catalist Rules**”), all of the resolutions set out in the Notice of the Annual General Meeting (“**AGM**”) dated 4 September 2024 were duly passed by way of poll, at the AGM held on 26 September 2024.

(a) The results of the poll on the resolutions put to the vote at the AGM are as follows:

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against		
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	
Ordinary Business						
1	Re-election of Mr. Chong Weng Hoe as Director of the Company ⁽¹⁾	113,616,697	113,615,997	100.00%	700	0.00%
2	Re-election of Dr. Heah Sieu Min as Director of the Company ⁽²⁾	113,616,697	113,615,997	100.00%	700	0.00%
3	Directors’ Fees of S\$122,000/- for the financial year ended 31 May 2024	113,616,697	113,615,997	100.00%	700	0.00%
4	Declaration of final dividend (tax-exempt one-tier) of S\$0.007 per ordinary share for the financial year ended 31 May 2024	113,616,697	113,615,997	100.00%	700	0.00%

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against		
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	
Ordinary Business						
5	Re-appointment of Messrs BDO LLP as auditors of the Company	113,168,697	113,167,997	100.00%	700	0.00%
Special Business						
6	Authority to issue ordinary shares	112,250,697	112,249,997	100.00%	700	0.00%
7	Authority to issue shares under the HCSS Performance Share Plan	113,616,697	113,614,997	100.00%	1,700	0.00%
8	Authority to issue shares under the HCSS Employee Share Option Scheme	113,616,697	113,614,997	100.00%	1,700	0.00%

Notes:

- (1) Mr. Chong Weng Hoe, who was re-elected as a Director under Resolution 1, remains as the Independent Non-executive Director, Chairman of the Board, Remuneration Committee and Nominating Committee, and a member of the Audit and Risk Management Committee of the Company. The Board of Directors of the Company considers Mr. Chong Weng Hoe to be independent for the purpose of Rule 704(7) of the Catalist Rules.
- (2) Dr. Heah Sieu Min, who was re-elected as a Director under Resolution 2, remains as the Executive Director and CEO of the Company.
- (b) Details of parties who are required to abstain from voting on any resolution(s), including number of shares held and the individual resolution(s) on which they are required to abstain from voting.
- No party was required to abstain from voting on any resolutions at the AGM.
- (c) Name of firm appointed as Scrutineer:
- Entrust Advisory Pte. Ltd. was appointed as the scrutineer for the AGM.

By Order of the Board

Dr. Heah Sieu Min
Executive Director and Chief Executive Officer

Date: 26 September 2024

About HC Surgical Specialists Limited

HC Surgical Specialists Limited (the “Company”) was incorporated on 1 September 2015 in Singapore and listed on the Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures across a network of 18 clinics located throughout Singapore.

This announcement has been prepared by the Company and reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd. (the “Sponsor”), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.